JP2021155431A5 - - Google Patents

Download PDF

Info

Publication number
JP2021155431A5
JP2021155431A5 JP2021100601A JP2021100601A JP2021155431A5 JP 2021155431 A5 JP2021155431 A5 JP 2021155431A5 JP 2021100601 A JP2021100601 A JP 2021100601A JP 2021100601 A JP2021100601 A JP 2021100601A JP 2021155431 A5 JP2021155431 A5 JP 2021155431A5
Authority
JP
Japan
Prior art keywords
acid sequence
seq
amino acid
set forth
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021100601A
Other languages
English (en)
Japanese (ja)
Other versions
JP7242760B2 (ja
JP2021155431A (ja
Filing date
Publication date
Priority claimed from JP2017552082A external-priority patent/JP6901400B2/ja
Application filed filed Critical
Publication of JP2021155431A publication Critical patent/JP2021155431A/ja
Publication of JP2021155431A5 publication Critical patent/JP2021155431A5/ja
Priority to JP2023035685A priority Critical patent/JP2023063377A/ja
Application granted granted Critical
Publication of JP7242760B2 publication Critical patent/JP7242760B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021100601A 2015-04-03 2021-06-17 TGF-β及びPD-1の阻害物質を使用する癌の治療法 Active JP7242760B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023035685A JP2023063377A (ja) 2015-04-03 2023-03-08 TGF-β及びPD-1の阻害物質を使用する癌の治療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562143016P 2015-04-03 2015-04-03
US62/143,016 2015-04-03
US201562191797P 2015-07-13 2015-07-13
US62/191,797 2015-07-13
JP2017552082A JP6901400B2 (ja) 2015-04-03 2016-04-03 TGF−β及びPD−1の阻害物質を使用する癌の治療法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017552082A Division JP6901400B2 (ja) 2015-04-03 2016-04-03 TGF−β及びPD−1の阻害物質を使用する癌の治療法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023035685A Division JP2023063377A (ja) 2015-04-03 2023-03-08 TGF-β及びPD-1の阻害物質を使用する癌の治療法

Publications (3)

Publication Number Publication Date
JP2021155431A JP2021155431A (ja) 2021-10-07
JP2021155431A5 true JP2021155431A5 (cg-RX-API-DMAC7.html) 2022-05-09
JP7242760B2 JP7242760B2 (ja) 2023-03-20

Family

ID=56920908

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017552082A Active JP6901400B2 (ja) 2015-04-03 2016-04-03 TGF−β及びPD−1の阻害物質を使用する癌の治療法
JP2021100601A Active JP7242760B2 (ja) 2015-04-03 2021-06-17 TGF-β及びPD-1の阻害物質を使用する癌の治療法
JP2023035685A Pending JP2023063377A (ja) 2015-04-03 2023-03-08 TGF-β及びPD-1の阻害物質を使用する癌の治療法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017552082A Active JP6901400B2 (ja) 2015-04-03 2016-04-03 TGF−β及びPD−1の阻害物質を使用する癌の治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023035685A Pending JP2023063377A (ja) 2015-04-03 2023-03-08 TGF-β及びPD-1の阻害物質を使用する癌の治療法

Country Status (6)

Country Link
US (4) US10167334B2 (cg-RX-API-DMAC7.html)
EP (2) EP3277716B1 (cg-RX-API-DMAC7.html)
JP (3) JP6901400B2 (cg-RX-API-DMAC7.html)
CN (2) CN116327915A (cg-RX-API-DMAC7.html)
ES (1) ES2820768T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016161410A2 (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116327915A (zh) 2015-04-03 2023-06-27 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
HK1250033A1 (zh) 2015-07-13 2018-11-23 Cytomx Therapeutics Inc. 抗-pd-1抗体、可活化的抗-pd-1抗体、及其使用方法
US11638744B2 (en) * 2015-09-03 2023-05-02 Ono Pharmaceutical Co., Ltd. Immunity enhancing agent for cancer by Allergin-1 antagonist
FI3779447T3 (fi) 2016-03-15 2023-04-21 Inst Nat Sante Rech Med Menetelmä syöpään sairastuneen potilaan antitumoraalisen CD8+T -solun vasteen aktivoimiseen
WO2018129331A1 (en) * 2017-01-07 2018-07-12 Merck Patent Gmbh Dosing regimens and dosage forms for targeted tgf-b inhibition
AR110904A1 (es) * 2017-01-20 2019-05-15 Sanofi Sa ANTICUERPOS ANTI-TGF-b Y SU USO
AR110755A1 (es) 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
TW202506185A (zh) * 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
EA201991729A1 (ru) * 2017-01-20 2019-12-30 Санофи Антитела к tgf-бета и их применение
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗lag3抗体の製剤および抗lag3抗体と抗pd-1抗体との共製剤
EP3634437A4 (en) * 2017-05-19 2020-11-18 Case Western Reserve University COMPOSITIONS AND METHODS FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
CN111936490A (zh) 2017-11-20 2020-11-13 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
JP2021510153A (ja) 2018-01-05 2021-04-15 アイカーン スクール オブ メディシン アット マウント サイナイ 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物
CN112135613A (zh) * 2018-03-20 2020-12-25 西奈山伊坎医学院 激酶抑制剂化合物和组合物及使用方法
CN111821434A (zh) * 2019-04-17 2020-10-27 上海君实生物医药科技股份有限公司 抗pd-1抗体在制备治疗实体瘤的药物中的用途
MX2020011684A (es) * 2018-05-04 2020-12-10 Merck Patent Gmbh Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
SG11202013217PA (en) * 2018-07-03 2021-01-28 Catalent Pharma Solutions Llc Multifunctional protein molecules comprising decorin and use thereof
AU2019336197A1 (en) 2018-09-07 2021-02-18 Pfizer Inc. Anti-avb8 antibodies and compositions and uses thereof
WO2020076969A2 (en) 2018-10-10 2020-04-16 Tilos Therapeutics, Inc. Anti-lap antibody variants and uses thereof
US20210340240A1 (en) * 2018-10-18 2021-11-04 INSERM (Institut National de la Santé et de la Recherche Médicale Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
MX2021005394A (es) 2018-11-07 2021-07-06 Merck Sharp & Dohme Llc Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
WO2020104628A1 (en) * 2018-11-21 2020-05-28 Bioncotech Therapeutics S.L Nanoplexed poly(i:c) formulations and uses thereof
WO2020146345A1 (en) * 2019-01-07 2020-07-16 Children's Medical Center Corporation Methods of treating cancer using lsd1 inhibitors and/or tgf-beta inhibitors in combination with immunotherapy
EA202192130A1 (ru) 2019-01-30 2021-12-28 Сколар Рок, Инк. Специфичные к ltbp-комплексу ингибиторы tgf и их применение
WO2020248908A1 (zh) * 2019-06-10 2020-12-17 中国科学院广州生物医药与健康研究院 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物
CN110464841B (zh) * 2019-08-19 2020-05-22 启辰生生物科技(珠海)有限公司 免疫增强的药物组合物及其应用
CN110734498A (zh) * 2019-10-15 2020-01-31 上海科棋药业科技有限公司 一种用于解除免疫抑制的融合蛋白及其应用
JP7495489B2 (ja) * 2019-10-21 2024-06-04 ナンチン リーズ バイオラブス カンパニー,リミティド PD-1およびTGFβを標的化する組換えタンパク質
AU2020375161A1 (en) * 2019-11-01 2022-05-19 Ares Trading S.A. Combined inhibition of PD-1, TGFβ and ATM together with radiotherapy for the treatment of cancer
JP2023507190A (ja) * 2019-12-20 2023-02-21 ノバルティス アーゲー 増殖性疾患を治療するための抗TGFβ抗体及びチェックポイント阻害薬の使用
CN115190812A (zh) 2020-01-11 2022-10-14 供石公司 TGFβ抑制剂及其用途
CA3166328A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
US20230072133A1 (en) * 2020-02-25 2023-03-09 WuXi Biologics Ireland Limited A bifunctional fusion protein and uses thereof
MX2022013620A (es) * 2020-04-29 2023-01-30 Chia Tai Tianqing Pharmaceutical Group Co Ltd Proteina bifuncional frente a pd-1 y tgf-beta.
JP7419168B2 (ja) * 2020-06-10 2024-01-22 株式会社東芝 改変型piggyBacトランスポゼースのポリペプチド、それをコードするポリヌクレオチド、導入キャリア、キット、細胞のゲノムに目的配列を組込む方法及び細胞製造方法
WO2022063193A1 (zh) * 2020-09-24 2022-03-31 上海齐鲁制药研究中心有限公司 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
TW202304979A (zh) * 2021-04-07 2023-02-01 瑞士商諾華公司 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
US20240301073A1 (en) 2021-07-14 2024-09-12 Scholar Rock, Inc. LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF
AU2022355388A1 (en) * 2021-09-30 2024-03-14 Betta Pharmaceuticals Co., Ltd Bispecific antibody and application thereof
KR102763607B1 (ko) * 2021-10-05 2025-02-07 주식회사 인게니움테라퓨틱스 자연살해 세포의 활성 향상용 조성물
CN116327956B (zh) * 2022-04-01 2025-11-28 劲方医药科技(上海)股份有限公司 药物组合物、其用途及癌症的治疗方法
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
KR0185192B1 (ko) 1989-10-05 1999-04-01 제임스 더블유. 데이비 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU1545692A (en) 1991-03-01 1992-10-06 Protein Engineering Corporation Process for the development of binding mini-proteins
US5658727A (en) 1991-04-10 1997-08-19 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ATE381614T1 (de) 1992-07-24 2008-01-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6664114B1 (en) 1992-08-03 2003-12-16 Sapidyne Instruments, Inc. Solid phase assay for detection of ligands
EP0670905B1 (en) 1992-09-22 2003-07-23 Biofocus Discovery Limited Recombinant viruses displaying a nonviral polypeptide on their external surface
US6054287A (en) 1994-05-27 2000-04-25 Methodist Hospital Of Indiana, Inc. Cell-type-specific methods and devices for the low temperature preservation of the cells of an animal species
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US20030044772A1 (en) 1997-08-04 2003-03-06 Applied Molecular Evolution [Formerly Ixsys] Methods for identifying ligand specific binding molecules
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
WO2001024812A1 (en) 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc TGF−βII型受容体に対するヒトモノクローナル抗体及びその医薬用途
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
MXPA03004793A (es) 2000-11-30 2004-12-03 Medarex Inc Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos.
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
DK1527100T3 (da) 2002-03-29 2009-09-07 Schering Corp Humane monoklonale antistoffer mod interleukin-5 og fremgangsm der og sammens tninger omfattende samme
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Pd−1に対する抗体およびその使用
JP4532409B2 (ja) 2003-01-23 2010-08-25 小野薬品工業株式会社 ヒトpd−1に対し特異性を有する物質
US7369111B2 (en) 2003-04-29 2008-05-06 Samsung Electronics Co., Ltd. Gate driving circuit and display apparatus having the same
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
EP1796715A2 (en) 2004-09-22 2007-06-20 Genzyme Corporation USE OF TGF-ß ANTAGONISTS TO LIMIT NEPHROTOXICITY OF IMMUNOSUPPRESSIVE AGENTS
TR201901929T4 (tr) 2005-02-08 2019-03-21 Genzyme Corp TGFBeta'ya antikorlar.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
AU2006330542B2 (en) 2005-12-23 2012-05-24 Eli Lilly And Company TGF-beta binding compositions
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
WO2010029435A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
HUE030807T2 (en) 2008-09-26 2017-05-29 Dana Farber Cancer Inst Inc Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제
TWI605828B (zh) 2008-12-09 2017-11-21 建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
EP2393835B1 (en) 2009-02-09 2017-04-05 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
MX351600B (es) 2011-06-03 2017-10-20 Xoma Technology Ltd Anticuerpo especificos para tgf-beta.
WO2013134365A1 (en) * 2012-03-08 2013-09-12 Ludwig Institute For Cancer Research Ltd TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
HUE060420T2 (hu) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
JP6731346B2 (ja) * 2014-02-10 2020-07-29 メルク パテント ゲーエムベーハー 標的TGFβ阻害
CN116327915A (zh) 2015-04-03 2023-06-27 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症

Similar Documents

Publication Publication Date Title
JP2021155431A5 (cg-RX-API-DMAC7.html)
JP2018518454A5 (cg-RX-API-DMAC7.html)
JP2022050618A5 (cg-RX-API-DMAC7.html)
JP2024153803A5 (cg-RX-API-DMAC7.html)
JP2019515008A5 (cg-RX-API-DMAC7.html)
KR102349056B1 (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
JP2019503361A (ja) がんを治療するための抗pd−1抗体と二重特異性抗cd20/抗cd3抗体の組合せ
JP2020508317A5 (cg-RX-API-DMAC7.html)
JP2025108509A (ja) がんを処置するためのクローディン18.2に対する抗体と免疫チェックポイント阻害剤を伴う併用療法
JP2017500057A5 (cg-RX-API-DMAC7.html)
WO2021182573A1 (ja) 癌の治療及び/又は予防のための医薬品
JP2024513138A (ja) がんを処置するためのクローディン18.2に対する抗体を伴う併用療法
Ströhlein et al. The current status of immunotherapy in peritoneal carcinomatosis
JPWO2022270524A5 (cg-RX-API-DMAC7.html)
WO2022270524A1 (ja) 癌の治療及び/又は予防のための医薬品
Han et al. Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo
Zhang et al. Cytotoxicity of cytokine‑induced killer cells targeted by a bispecific antibody to gastric cancer cells
JP7715041B2 (ja) 癌の治療及び/又は予防のための医薬品
TW201906634A (zh) 併用包含溶血性鏈球菌之菌體的製劑的療法
WO2021182570A1 (ja) 癌の治療及び/又は予防のための医薬品
JPWO2020232019A5 (cg-RX-API-DMAC7.html)
Watanabe et al. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody
JPWO2020043683A5 (cg-RX-API-DMAC7.html)
CN115154612A (zh) 药物组合物及其在制备抗肿瘤的联合治疗药物中的应用
WO2021182572A1 (ja) 癌の治療及び/又は予防のための医薬品